PI Industries Limited has announced it will hold a virtual interaction with Blackrock Asset on May 26, 2026. The meeting is scheduled as a one-on-one session under Regulation 30(6) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The company stated that no unpublished price sensitive information is proposed to be shared during the aforesaid meeting. The interaction is subject to change due to exigencies on the part of the investors or the company.

Meeting Details

The following table outlines the specifics of the scheduled interaction:

The disclosure was made to inform the stock exchanges and analysts about the upcoming corporate interaction.

PI Industries has come under the spotlight of multiple brokerages following a disappointing Q4 performance, with analysts divided on the company's near-term prospects. The results revealed EBITDA and PAT misses driven by a combination of slower new product growth, a sharp contraction in pyroxasulfone volumes, lower CSM exports, and elevated overheads—prompting a range of target price revisions and rating reaffirmations across the Street.

Analyst Ratings and Target Prices at a Glance

The divergence in analyst views is stark, with price targets spanning from ₹2556 to ₹3883. The table below summarises the current stance of each brokerage:

Constructive Views: Jefferies and Morgan Stanley

Jefferies maintains a Buy rating with a target price of ₹3575, acknowledging the Q4 EBITDA and PAT miss stemming from slower new product growth, a sharp contraction in pyroxasulfone, and higher working capital. Despite these near-term headwinds, Jefferies expects an FY27 recovery supported by a favorable base and new molecule growth. The brokerage projects a 12% adjusted PAT CAGR over FY26–28.

Morgan Stanley retains an Overweight rating with a target price of ₹3,883, pointing to an expected return to revenue growth in FY27. The brokerage highlights several potential catalysts:

• Improving exports and domestic agchem traction
• Strong margins in the Biologicals segment
• Pharma scale-up potential
• US approval for the company's bionematocide product
• Upcoming Pioxaniliprole launch in India

Neutral Stance: HSBC

HSBC maintains a Hold rating with a target price of ₹3000, citing another weak Q4FY26 earnings miss attributed to agri business disappointment and higher overheads pressuring margins. The brokerage flags uncertainty around muted core businesses and the slower-than-expected scaling of new business verticals, which has led to earnings cuts.

Cautious Views: Citi and DAM Capital

On the more cautious end of the spectrum, Citi maintains a Sell rating with a target price of ₹2600. The brokerage points to weak Q4 EBITDA driven by lower CSM exports and agchem revenues, continued losses in Pharma CDMO despite growth, and margin pressure. Citi also flags back-ended FY27 recovery expectations, concerns over pyroxasulfone generic competition, and a muted agchem outlook as key risks.

DAM Capital similarly maintains a Sell rating with a target price of ₹2556, citing structural challenges in Agchem CSM, a sharp slowdown in legacy exports, weak domestic agchem demand, and delayed recovery in Biologicals and exports. The brokerage also notes margin pressure from higher costs and R&D spend, and has made EPS cuts for FY27 and FY28 due to a muted growth outlook.

Key Concerns Across the Street

Despite differing ratings, several themes emerge consistently across analyst reports:

• Pyroxasulfone headwinds: Sharp volume contraction and rising generic competition remain a recurring concern
• CSM export slowdown: Legacy export momentum has weakened, weighing on near-term revenue visibility
• Margin pressure: Higher overheads, R&D spend, and Pharma CDMO losses are compressing profitability
• Delayed recovery: FY27 recovery expectations are largely back-ended and contingent on new product ramp-ups
• Domestic agchem weakness: Muted demand in the domestic market adds to near-term uncertainty

The breadth of analyst opinion on PI Industries reflects the complexity of its current business transition, as the company navigates legacy product headwinds while investing in new molecules, biologicals, and pharma capabilities. The FY27 trajectory will be closely watched for signs of the recovery that bullish analysts anticipate.